«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2024 22

Page:

4355-4358

Research Field:

Publishing date:

Info

Title:

Clinical analysis of 7 cases of acute myeloid leukemia t(11;19)(q23;p13) and review of literatures

Author(s):

CHEN Yingyi; ZHAO Yu; BAI Anbo; HU Jieying; GAO Shaobing

Central Laboratory,the Affiliated Cancer Hospital of Zhengzhou University （Henan Cancer Hospital）,Henan Zhengzhou 450008,China.

Keywords:

acute myeloid leukemia; t(11; 19)(q23; p13); KMT2A-ELL

PACS:

R730.5

DOI:

10.3969/j.issn.1672-4992.2024.22.023

Abstract:

Objective:To analyze the clinical characteristics and prognosis of 7 acute myeloid leukemia (AML) patients with t(11;19)(q23;p13).Methods:7 cases of t(11;19)(q23;p13) AML patients in our hospital from December 2014 to December 2023 were included to review clinical data,chromosome karyotyping,fusion gene,immunophenotype,treatment regimen and efficacy,with review of related literatures.Results:FAB type of 7 AML patients:4 cases of AML-M4 and 3 cases of AML-M5,all with KMT2A-ELL fusion gene positive at initial diagnosis.Immunophenotype:All the 7 patients expressed HLA-DR,CD13,CD33,CD38,while 6 patients expressed CD117,which was consistent with the characteristics of myeloid antigens.All the 7 patients received chemotherapy,and 6 of them received allogeneic hematopoietic stem cell transplantation (allo-HSCT) after chemotherapy.By the end of the follow-up on December 21,2023,five of the seven patients died and only two surviving,with a median overall survival of 9(3~69) months.Conclusion:The t(11;19)(q23;p13) abnormality is one of the rare chromosomal translocations in hematological malignancies that is found mostly in acute myeloid leukemia with a poor prognosis.

References:

［1］ SHIMONY S,STAHL M,STONE RM.Acute myeloid leukemia:2023 update on diagnosis,risk-stratification,and management［J］.Am J Hematol,2023,98(3):502-526.
［2］ CARTER JL,HEGE K,YANG J,et al.Targeting multiple signaling pathways:the new approach to acute myeloid leukemia therapy［J］.Signal Transduct Target Ther,2020,5(1):288.
［3］ PELCOVITS A,NIROULA R.Acute myeloid leukemia:A review［J］.R I Med J (2013),2020,103(3):38-40.
［4］ 李振燕.流式免疫分型联合骨髓细胞形态学分型在急性白血病诊断中的应用［J］.实用检验医师杂志,2022,14(02):133-136. LI ZY.Application of flow immunotyping combined with bone marrow cell morphological typing in diagnosis of acute leukemia［J］.Chinese Journal of Clinical Pathologist,2022,14(02):133-136.
［5］ MOORMAN AV,HAGEMEIJER A,CHARRIN C,et al.The translocations,t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3):a cytogenetic and clinical profile of 53 patients.European 11q23 Workshop participants［J］.Leukemia,1998,12(5):805-810.
［6］ GRIMWADE D,HILLS RK,MOORMAN AV,et al.Refinement of cytogenetic classification in acute myeloid leukemia:determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials［J］.Blood,2010,116(3):354-365.
［7］ ZHAO X,LI S,LI N,et al.11q23 abnormalities in adult Chinese patients with hematological malignancies［J］.Med Oncol,2014,31(8):115.
［8］ 李丽,崔成华,徐建宁,等.21例伴t(11;19)(q23;p13)白血病的临床和实验室特征［J］.临床输血与检验,2019,21(01):87-91+38. LI L,CUI CH,XU JN,et al.Clinical and laboratory characteristics of the patients with leukemia t(11;19)(q23;p13)［J］.Journal of Clinical Transfusion and Laboratory Medicine,2019,21(01):87-91+38.
［9］ MEYER C,LARGHERO P,ALMEIDA LOPES B,et al.The KMT2A recombinome of acute leukemias in 2023［J］.Leukemia,2023,37(5):988-1005.
［10］ SHAH CA,BEI L,WANG H,et al.The leukemia-associated MLL-ELL oncoprotein induces fibroblast growth factor 2 (Fgf2)-dependent cytokine hypersensitivity in myeloid progenitor cells［J］.J Biol Chem,2013,288(45):32490-32505.
［11］ BEI L,SHAH C,WANG H,et al.Regulation of CDX4 gene transcription by HoxA9,HoxA10,the MLL-ELL oncogene and Shp2 during leukemogenesis［J］.Oncogenesis,2014,3(12):e135.
［12］ TAKAHASHI S,KANAI A,OKUDA H,et al.HBO1-MLL interaction promotes AF4/ENL/P-TEFb-mediated leukemogenesis［J］.Elife,2021,10:e65872.
［13］ YOKOYAMA A.Leukemogenesis via aberrant self-renewal by the MLL/AEP-mediated transcriptional activation system［J］.Cancer Sci,2021,112:3935-3944.
［14］ WINTERS AC,BERNT KM.MLL-rearranged leukemias-an update on science and clinical approaches［J］.Front Pediatr,2017,5:4.
［15］ JIANG B,ZHAO Y,LUO Y,et al.Outcomes of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia harboring KMT2A rearrangement and its prognostic factors［J］.Cell Transplant,2024,33:9636897231225821.
［16］ TAO S,SONG L,DENG Y,et al.Successful treatment of two relapsed patients with t(11;19)(q23;p13) acute myeloid leukemia by CLAE chemotherapy sequential with allogeneic hematopoietic stem cell transplantation:Case reports［J］.Oncol Lett,2021,21(3):178.
［17］ MUTO T,TAKEUCHI M,YAMAZAKI A,et al.Efficacy of myeloablative allogeneic hematopoietic stem cell transplantation in adult patients with MLL-ELL-positive acute myeloid leukemia［J］.Int J Hematol,2015,102(1):86-92.

Memo

Memo:

河南省重点研发与推广专项(科技攻关)项目(编号：222102310579)

Common functions

Last Update: 1900-01-01